Literature DB >> 3152465

National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987.

.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 3152465

Source DB:  PubMed          Journal:  Neurofibromatosis        ISSN： 1010-5662


× No keyword cloud information.
  101 in total

1.  [18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: correlation with malignant transformation.

Authors:  L L Tsai; L Drubach; F Fahey; M Irons; S Voss; N J Ullrich
Journal:  J Neurooncol       Date:  2012-03-11       Impact factor: 4.130

2.  Spontaneous aortic rupture in a patient with neurofibromatosis type 1.

Authors:  Yang Jin Park; Keun Myoung Park; Jiyoung Oh; Hong Suk Park; Jung-Sun Kim; Young-Wook Kim
Journal:  J Korean Surg Soc       Date:  2012-03-27

Review 3.  Neurocutaneous Disorders for the Practicing Neurologist: a Focused Review.

Authors:  Anna Carolina Paiva Costa T Figueiredo; Nikolas Mata-Machado; Matthew McCoyd; José Biller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

4.  Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.

Authors:  Mahendranath Moharir; Kevin London; Robert Howman-Giles; Kathryn North
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-24       Impact factor: 9.236

5.  Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Authors:  Brigitte C Widemann; Dusica Babovic-Vuksanovic; Eva Dombi; Pamela L Wolters; Stewart Goldman; Staci Martin; Anne Goodwin; Wendy Goodspeed; Mark W Kieran; Bruce Cohen; Susan M Blaney; Allison King; Jeffrey Solomon; Nicholas Patronas; Frank M Balis; Elizabeth Fox; Seth M Steinberg; Roger J Packer
Journal:  Pediatr Blood Cancer       Date:  2014-04-22       Impact factor: 3.167

6.  Rare Presentation of Neurofibromatosis and Turner Syndrome in a Pediatric Patient.

Authors:  Natalie Gengel; Ian Marshall
Journal:  Pediatr Rep       Date:  2017-06-27

7.  Extensive Retropharyngeal and Spinal Plexiform Neurofibromas in a Neonate with Type 1-Neurofibromatosis.

Authors:  Meghmala Sadhukhan; Brendon Conry; Bim Bhaduri
Journal:  Indian J Pediatr       Date:  2017-04-25       Impact factor: 1.967

8.  Oncologic outcomes of sporadic, neurofibromatosis-associated, and radiation-induced malignant peripheral nerve sheath tumors.

Authors:  Jennifer LaFemina; Li-Xuan Qin; Nicole H Moraco; Cristina R Antonescu; Ryan C Fields; Aimee M Crago; Murray F Brennan; Samuel Singer
Journal:  Ann Surg Oncol       Date:  2012-08-10       Impact factor: 5.344

9.  Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Authors:  Brigitte C Widemann; Eva Dombi; Andrea Gillespie; Pamela L Wolters; Jean Belasco; Stewart Goldman; Bruce R Korf; Jeffrey Solomon; Staci Martin; Wanda Salzer; Elizabeth Fox; Nicholas Patronas; Mark W Kieran; John P Perentesis; Alyssa Reddy; John J Wright; AeRang Kim; Seth M Steinberg; Frank M Balis
Journal:  Neuro Oncol       Date:  2014-02-04       Impact factor: 12.300

10.  Cerebral arteriopathy in neurofibromatosis type 1.

Authors:  Rk Sanjeev; S Kumaravelu
Journal:  Med J Armed Forces India       Date:  2012-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.